ADVIA CHEMISTRY REAGENTS, AND ADVIA CHEMISTRY B2-MICROGLOBULIN CALIBRATOR

K110874 · Siemens Healthcare Diagnostics, Inc. · JZG · Jan 20, 2012 · Immunology

Device Facts

• Record ID: K110874
• Device Name: ADVIA CHEMISTRY REAGENTS, AND ADVIA CHEMISTRY B2-MICROGLOBULIN CALIBRATOR
• Applicant: Siemens Healthcare Diagnostics, Inc.
• Product Code: JZG · Immunology
• Decision Date: Jan 20, 2012
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5630
• Device Class: Class 2

Indications for Use

Reagent: for in vitro diagnostic use in the quantitative determination of β2-microglobulin in human serum or plasma (lithium heparin and potassium EDTA) on ADVIA® 1650 Chemistry systems. The ADVIA 1650 Chemistry 32-Microglobulin (B2M) assay aids in the diagnosis of active rheumatoid arthritis and kidney disease. Calibrators: for in vitro diagnostic use in the calibration of ADVIA® Chemistry systems for the ADVIA Chemistry β2-Microglobulin method.

Device Story

Assay measures β2-microglobulin in human serum/plasma using latex-enhanced immunoturbidimetric principle. Sample diluted and reacted with buffer containing latex particles coated with goat anti-human β2-microglobulin antibodies. Antigen-antibody complex formation increases turbidity, measured via light absorbance at 545nm. Concentration determined by standard curve constructed from reagent blank and single-level calibrator. Used on ADVIA® 1650 Chemistry systems in clinical laboratory settings by trained personnel. Output provides quantitative β2-microglobulin levels to assist clinicians in diagnosing active rheumatoid arthritis and kidney disease.

Clinical Evidence

Bench testing only. Precision evaluated per CLSI EP5-A2 (n=80/sample, CVs 2.0-3.3%). Linearity (0.25-18.00 mg/L) confirmed with 93.6-104.0% recovery. LoD/LoB determined per CLSI EP17-A (LoD 0.25 mg/L, LoB 0.20 mg/L). Method comparison with predicate (n=88) showed slope 1.03, intercept -0.38, R=0.996. Matrix equivalency (serum vs plasma) confirmed. Reference range (1.0-2.4 mg/L) established using 120 healthy adults.

Technological Characteristics

Turbidimetric immunoassay; latex particles coated with goat anti-β2-microglobulin antibodies. Analyzed on ADVIA 1650 Chemistry system. Reagent storage 2-8°C. Calibrator is lyophilized, buffer-based, bovine serum albumin and human β2-microglobulin. Traceable to WHO 1st International Standard.

Indications for Use

Indicated for the quantitative determination of β2-microglobulin in human serum or plasma (lithium heparin and potassium EDTA) to aid in the diagnosis of active rheumatoid arthritis and kidney disease.

Regulatory Classification

Identification

A beta-2-microglobulin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques beta-2-microglobulin (a protein molecule) in serum, urine, and other body fluids. Measurement of beta-2-microglobulin aids in the diagnosis of active rheumatoid arthritis and kidney disease.

Special Controls

*Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.

Predicate Devices

• Siemens N Latex β2 – Microglobulin (N B2M) (k002731)
• Siemens N-protein standard SL (k052788)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number:
k110874

B. Purpose for Submission:
New device

C. Measurand:
$\beta 2$-Microglobulin

D. Type of Test:
Quantitative, latex-enhanced immunoturbidimetric

E. Applicant:
Siemens Healthcare Diagnostics, Inc.

F. Proprietary and Established Names:
ADVIA® Chemistry $\beta 2$-Microglobulin reagent
ADVIA® Chemistry $\beta 2$-Microglobulin calibrator

G. Regulatory Information:

1. Regulation section:
21 CFR §866.5630 Beta-2-Microglobulin Immunological Test System
21 CFR §862.1150 Calibrator

2. Classification:
Class II

3. Product code:
JZG, Beta-2 Microglobulin Immunological Test System
JIT, Calibrator, Secondary

4. Panel:
Immunology (82)
Clinical Chemistry (75)

H. Intended Use:

1. Intended use(s):
Reagent: For in vitro diagnostic use in the quantitative determination of $\beta 2$-microglobulin in human serum and plasma (lithium heparin and potassium EDTA) on ADVIA® 1650 Chemistry systems. The ADVIA® 1650 Chemistry $\beta 2$-Microglobulin (B2M) assay aids in the diagnosis of active rheumatoid arthritis and kidney disease.
Calibrators: For in vitro diagnostic use in the calibration of ADVIA® 1650 Chemistry systems for the ADVIA® Chemistry $\beta 2$-Microglobulin method.

2. Indication(s) for use:
Same as above

3. Special conditions for use statement(s):
For prescription use only

4. Special instrument requirements:
ADVIA® 1650 Chemistry Systems

I. Device Description:
The ADVIA® 1650 Chemistry $\beta 2$-Microglobulin reagent consists of the following:
Reagent 1 in a $20\,\mathrm{mL}$ container, consisting of $0.5\%$ bovine serum albumin, Tris buffer

{1}

(pH 8.2) and sodium azide; Reagent 2 in a 20-mL container, consisting of latex-particles coated with antihuman β2-microglobulin antibodies (goat), Tris buffer (pH 8.0) and sodium azide. The components of the package are available as a kit only. The ADVIA® 1650 Chemistry β2-Microglobulin calibrator is a lyophilized, buffer-based product containing bovine serum and human β2-microglobulin. The kit consists of 3 vials of a single level calibrator. The calibrator requires reconstitution with 1 mL of distilled water prior to use.

# J. Substantial Equivalence Information:

1. Predicate device name (s) and 510(k) numbers:

N Latex β2-Microglobulin, k002731

N/T Protein Standard SL, k052788

2. Comparison with predicate:

| Assay Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Intended Use/Indication for Use | For in vitro diagnostic use in the quantitative determination of β2-microglobulin in human serum or plasma as an aid in the diagnosis of active rheumatoid arthritis and kidney disease. | Same |
| Measurement | Quantitative | Same |
| Storage Temperature | 2-8°C | Same |
| Format | Liquid | Same |
| Use of Calibrators | Yes | Same |
| Assay Differences | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Platform | ADVIA® 1650 Chemistry System | BN system |
| Assay Principle | Turbidimetric | Nephelometric |
| On Board Stability | 21 days | Minimum 5 days |
| Sample Type | Serum, plasma | Serum, plasma, urine |
| Antibody Source | Goat polyclonal antibody | Mouse polyclonal antibody |
| Assay Range | 0.25 – 18.0 mg/L | 0.7 – 23.0 mg/L (serum/plasma) |
| Reference Range (Expected Values) | 1.0 to 2.4 mg/L | 1.09 to 2.53 mg/L |
| Calibrator Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Number of Calibrators | 1 | Same |
| Storage temperature | 2-8°C | Same |

{2}

| Calibrator Differences | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Number of Analytes | One | Multiple |
| Format | Lyophilized – buffer based | Liquid – serum based |
| Stability | 30 days after reconstitution | 14 days after opening |
| Instrument | ADVIA® 1650 Chemistry System | BN Systems |

# K. Standard/Guidance Document Referenced:

CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods; Clinical and Laboratory Standards Institute; 2004.

CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation; Clinical and Laboratory Standards Institute; 2004.

# L. Test Principle:

In the ADVIA® 1650 Chemistry $\beta 2$ -Microglobulin assay, a sample is diluted and reacted with a buffer that contains latex particles coated with antibody specific for $\beta 2$ -microglobulin. The formation of the antibody-antigen complex during the reaction results in an increase in turbidity, the extent of which is measured as the amount of light adsorbed at $545\mathrm{nm}$ . The $\beta 2$ -microglobulin concentration in a sample is determined by constructing a standard curve from the absorbance of a reagent blank and a single-level calibrator.

# M. Performance Characteristics:

# 1. Analytical performance:

# a. Precision/Reproducibility:

A precision study was conducted in accordance with CLSI document EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline. Five samples were used for the study including two $\beta 2$ -microglobulin-spiked serum pools (i.e., Pool 1 and Pool 2) and three serum-based liquid controls (i.e., Control 1, Control 2, Control 3) that were prepared by spiking a pool of serum samples with $\beta 2$ -microglobulin. All samples were analyzed in duplicate per run with 2 runs per day for 20 days using two reagent lots and two systems with one operator. The results are summarized below:

| Serum Sample | No. of Rep | Mean Spiked B2M (mg/L) | Within Run | | Between Run | | Between Day | | Total | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | SD mg/L | CV % | SD mg/L | CV % | SD mg/L | CV % | SD mg/L | CV % |
| Control 1 | 80 | 0.74 | 0.01 | 1.8 | 0.02 | 2.3 | 0.01 | 1.4 | 0.02 | 3.3 |
| Control 2 | 80 | 1.77 | 0.02 | 1.0 | 0.01 | 0.4 | 0.04 | 2.4 | 0.05 | 2.6 |
| Control 3 | 80 | 3.68 | 0.04 | 1.1 | 0.03 | 0.9 | 0.07 | 1.9 | 0.09 | 2.4 |
| Pool 1 | 78[1] | 12.52 | 0.06 | 0.5 | 0.11 | 0.9 | 0.22 | 1.8 | 0.26 | 2.1 |
| Pool 2 | 80 | 17.43 | 0.20 | 1.1 | 0.10 | 0.6 | 0.27 | 1.6 | 0.35 | 2.0 |

Note: [1]2 replicates were mislabeled and thus excluded from the analysis.

# b. Linearity/assay reportable range:

Serum linearity across the assay range (0.25 to $18.00\mathrm{mg / L}$ ) was evaluated by

{3}

testing nine serum samples with concentrations of $\beta 2$-microglobulin evenly distributed throughout the assay range. The series of nine serum samples were prepared by dilution of a sample with high concentration of $\beta 2$-microglobulin (approximately $18.88~\mathrm{mg / L}$) with a fresh normal human serum sample with an undetectable level of $\beta 2$-microglobulin. Each sample was tested in three replicates. The $\%$ recovery was calculated as the difference of the expected values and the observed values. The $\%$ recovery ranged from $93.6\%$ to $104.0\%$, which met the established acceptance criteria. In addition, linear regression of observed values versus expected values showed that the slope, intercept and $\mathbf{r}^2$ were 0.9963, -0.0989 (mg/L) and 0.9987, respectively.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

**Traceability:**

The ADVIA® 1650 Chemistry $\beta 2$-Microglobulin assay is calibrated using the ADVIA® Chemistry $\beta 2$-Microglobulin Calibrator. The calibrator is traceable to WHO $1^{\text{st}}$ International Preparation for $\beta 2$-microglobulin (NIBSC Code# B2M).

**Value Assignment of Calibrators:**

The values of the Master Lot of Calibrators were initially assigned based on Siemens N-latex $\beta 2$-Microglobulin method and then confirmed by acceptable recovery of the WHO first International Standard for $\beta 2$-microglobulin (NIBSC Code# B2M). The values of the ADVIA® Chemistry $\beta 2$-Microglobulin Calibrators in each production lot are assigned based on recovery of the Master Lot Calibrator and confirmed by testing of controls and Master Lot Calibrators as samples in triplicate using the $\beta -2$ Microglobulin method calibrated with the new production lot of calibrators with the newly assigned values.

**Stability:**

Real time stability studies were performed to support the following stability claims of the ADVIA® Chemistry $\beta 2$-Microglobulin reagents and ADVIA® $\beta 2$-Microglobulin Calibrator:

- Onboard stability is 21 days with a calibration frequency of 21 days.
- Shelf-life stability of the unopened ADVIA® Chemistry $\beta 2$-Microglobulin reagent stored at $2 - 8^{\circ}\mathrm{C}$ is 18 months.
- Shelf-life stability of the unopened ADVIA® Chemistry $\beta 2$-Microglobulin calibrators stored at $2 - 8^{\circ}\mathrm{C}$ is 24 months.
- Shelf-life stability of the opened (recapped) vial ADVIA® Chemistry $\beta 2$ Microglobulin calibrators stored at $2 - 8^{\circ}\mathrm{C}$ is 30 days.

d. Detection limit:

Testing for limit of detection (LoD) and limit of blank (LoB) was conducted in accordance with CLSI guideline EP-17A. Sixty replicates of a blank sample were used along with 60 replicates of a low serum sample (serum sample with an approximate concentration of $0.74\mathrm{mg / L}$). The following results were obtained:

$$
\mathrm{LoB} = 0.20\mathrm{mg / L}
$$

{4}

$$
\mathrm {L o D} = 0. 2 5 \mathrm {m g / L}
$$

# e. Analytical specificity:

Interference by endogenous and other substances was evaluated by testing $\beta 2$ -microglobulin at concentrations of approximately 1, 3 and $11\mathrm{mg / L}$ within the assay range. Aliquots of each serum pool were spiked with 5 equally diluted concentrations of the interferent. The five concentrations were prepared by diluting the pool with the highest concentration of interferent with the control pool without interferent. All samples were run in duplicate using one reagent lot on one system. The following is a list of the interferents and the respective highest concentrations that were tested: bilirubin (conjugated and unconjugated, $60~\mathrm{mg / dL}$ ); hemolysis (hemoglobin, $1000~\mathrm{mg / dL}$ ); lipemia (from intralipid, $1000~\mathrm{mg / dL}$ ); rheumatoid factor (RF, $2500~\mathrm{IU / mL}$ ) and ascorbic acid ( $50~\mathrm{mg / dL}$ , $100~\mathrm{mg / dL}$ , $150~\mathrm{mg / dL}$ and $200~\mathrm{mg / dL}$ ); acetone ( $1000~\mathrm{mg / dL}$ ); cholesterol ( $500~\mathrm{mg / dL}$ ); creatinine ( $500~\mathrm{mg / dL}$ ); ethanol ( $1000~\mathrm{mg / dL}$ ); glucose ( $2000~\mathrm{mg / dL}$ ); immunoglobulin G ( $5000~\mathrm{mg / dL}$ ); immunoglobulin M ( $1600~\mathrm{mg / dL}$ ); riboflavin ( $15~\mathrm{mg / dL}$ ); total protein ( $12~\mathrm{g / dL}$ ); urea ( $60~\mathrm{mg / dL}$ ) and uric acid ( $16~\mathrm{mg / dL}$ ). No significant interference (i.e., sample recovers $\pm 10\%$ ) was observed with the interferents tested with the exception of the following: ascorbic acid spiked at $100~\mathrm{mg / dL}$ to samples containing $1.21~\mathrm{mg / L}$ $\beta 2$ -microglobulin ( $-15.3\%$ ) and at $200~\mathrm{mg / dL}$ to samples containing $10.73~\mathrm{mg / L}$ $\beta 2$ -microglobulin ( $-13.4\%$ ).

# f. Assay cut-off: Not applicable.

# 2. Comparison studies:

# a. Method comparison with predicate device:

Performance of the ADVIA® 1650 Chemistry $\beta$ 2-Microglobulin assay was evaluated against the predicate, Siemens N Latex $\beta$ 2-Microglobulin (N B2M). The study included a total of 88 remnant serum specimens. Samples were analyzed on the ADVIA® 1650 Chemistry system using $\beta$ 2-Microglobulin reagent and on the predicate device in parallel on the same day. Samples were tested in duplicate on each system (ADVIA® Chemistry and predicate) using one lot of reagents for each system. Results from least squares linear regression of the data from the first replicates are summarized below.

| N | Range (mg/L) | Slope (95% Confidence Intervals) | Intercept (95% Confidence Intervals) | R | Syx (mg/L) |
| --- | --- | --- | --- | --- | --- |
| 88 | 0.65 – 16.00 | 1.03 (1.017 – 1.052) | -0.38 (-0.53 – -0.24) | 0.996 | 0.408 |

{5}

b. Matrix comparison:

Serum/Plasma equivalency studies were performed to support the use of lithium heparin and potassium EDTA tubes for the collection of serum and plasma samples. Fifty-seven matched sets of serum and plasma (lithium heparin and potassium EDTA) were used. Ten paired serum and plasma pairs (from the same donors) were spiked with $\beta 2$-microglobulin to achieve concentrations of $\beta 2$-microglobulin across the assay range. The samples were analyzed using the ADVIA® 1650 Chemistry $\beta 2$-Microglobulin method using one lot of reagent, in duplicate. Results from linear regression on the data from the first replicates are summarized below.

| Linear Regression | N | Range (mg/L) | Slope | Intercept | R | Syx (mg/L) |
| --- | --- | --- | --- | --- | --- | --- |
| Serum vs Lithium Heparin | 57 | 0.97 – 17.75 | 1.01 | 0.01 | 0.99 | 0.21 |
| Serum vs Potassium EDTA | 57 | 0.97 – 17.75 | 1.00 | -0.04 | 0.99 | 0.19 |

3. Clinical studies:

a. Clinical Sensitivity: Not applicable
b. Clinical specificity: Not applicable
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable
5. Expected values/Reference range: The reference range was determined by calculating the $2.5^{\text{th}}$ and the $97.5^{\text{th}}$ percentile generated from sera from 120 apparently healthy adults. Samples were analyzed in singlet using the ADVIA® 1650 Chemistry $\beta 2$-Microglobulin assay. The range was determined to be 1.0 to $2.4\,\mathrm{mg/L}$.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.